How to assess the value of medicines?

Frontiers in Pharmacology

Volumn SEP, Issue , 2010, Pages

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Economic evaluation; Incremental cost effectiveness ratio; Threshold; Value

Indexed keywords

EID: 84860873824     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00115     Document Type: Article

References (49)

1. European Commission. (2000). Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medici- nal products. Official Journal of the European Communities L 18/1.
2. Baltussen, R., and Niessen, L. (2006). Priority setting of health interven- tions: the need for multi-criteria decision analysis. Cost. Eff. Resour. Alloc. 4, 14.
3. Barrett, A., Roques, T., Small, M., and Smith, R. D. (2006). How much will Herceptin really cost? BMJ 333, 1118-1120.
4. Bayoumi, A. M. (2004). The measurement of contingent valuation for health economics. Pharmacoeconomics 22, 691-700.
5. Bell, C. M., Urbach, D. R., Ray, J. G., Bayoumi, A., Rosen, A. B., Greenberg, D., and Neumann, P. J. (2006). Bias in published cost effectiveness stud-ies: systematic review. BMJ 332, 699-703.
6. Birch, S., and Gafni, A. (2006a). " Decision rules in economic evaluation," in The Elgar Companion to Health Economics, ed. A. Jones (Northampton: Edward Elgar), 492-502.
7. Birch, S., and Gafni, A. (2006b). Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 24, 1121-1131.
8. Brazier, J., Ratcliffe, J., and Salomon, J. (2007). Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press.
9. Cleemput, I., and Van, W. P. (2009). History of health technology assess- ment in Belgium. Int. J. Technol. Assess. Health Care 25(Suppl. 1), 82-87.
10. Cohen, J., Stolk, E., and Niezen, M. (2007). The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 25, 727-734.
11. Denis, A., Simoens, S., Fostier, C., Mergaert, L., and Cleemput, I. (2009). Health technology assessment of policy gov- erning orphan diseases and orphan drugs Brussels.
12. Dolan, P., Shaw, R., Tsuchiya, A., and Williams, A. (2005). QALY max- imisation and people's preferences: a methodological review of the litera- ture. Health Econ. 14, 197-208.
13. Donaldson, C., and Gerard, K. (2005). Economics of Health Care Financing: The Visible Hand. Basingstoke: Palgrave Macmillan.
14. Drummond, M., Evans, B., LeLorier, J., Karakiewicz, P., Martin, D., Tugwell, P., and MacLeod, S. (2009). Evidence and values: requirements for public reimbursement of drugs for rare dis- eases - a case study in oncology. Can. J. Clin. Pharmacol. 16, e273-e281.
15. Drummond, M., Sculpher, M. J., Torrance, G. W., O'Brien, B. J., and Stoddart, G. L. (2005). Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.
16. Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P., and Jonsson, B. (2004). Use of cost-effectiveness analysis in health- care resource allocation decision- making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518-528.
17. European Commission. (2004). Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J. Eur. Union L136, 34-57.
18. European Generic Medicines Association. (2008). EGA Market Review (2007). Brussels: European Generic Medicines Association.
19. Gafni, A., and Birch, S. (2006). Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med. 62, 2091-2100.
20. Garber, A., and Phelps, C. (1997). Economic foundations of cost-ef- fectiveness analysis. J. Health Econ. 16, 1-31.
21. George, B., Harris, A., and Mitchell, A. (2001). Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reim- bursement in australia (1991 to 1996). Pharmacoeconomics 19, 1103-1109.
22. Godman, B., Wettermark, B., Hoffmann, M., Andersson, K., Haycox, A., and Gustafsson, L. L. (2009). Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83.
23. Grosse, S. D. (2008). Assessing cost-effec- tiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8, 165-178.
24. Health Care Insurance Board. (1999). Richtlijnen Voor Farmaco-Economisch Onderzoek (Guidelines for Pharmaco-Economic Research). Amstelveen: Health Care Insurance Board.
25. Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., and Weissert, W. G. (2000). Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making 20, 332-342.
26. Johannesson, M., and Jonsson, B. (1991). Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 17, 1-23.
27. Laupacis, A., Feeny, D., Detsky, A. S., and Tugwell, P. X. (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473-481.
28. Mason, H., Baker, R., and Donaldson, C. (2008). Willingness to pay for a QALY: past, present and future. Expert Rev. Pharmacoecon. Outcomes Res. 8, 575-582.
29. McCabe, C., Claxton, K., and Culyer, A. J. (2008). The NICE cost- effectiveness threshold: what it is and what that means. Pharmacoeconomics 26, 733-744.
30. Mitton, C., and Donaldson, C. (2004). Priority Setting Toolkit: A Guide to the Use of Economics in Healthcare Decision-Making. London: BMJ Books.
31. Mitton, C. R., and Donaldson, C. (2003). Setting priorities and allocating resources in health regions: lessons from a project evaluating program budgeting and marginal analysis (PBMA). Health Policy (New York) 64, 335-348.
32. National Institute for Health and Clinical Excellence. (2009). Appraising Life- Extending, End of Life Treatments. London: National Institute for Health and Clinical Excellence.
33. Owens, D. K. (1998). Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 13, 716-717.
34. PHARMAC. (2007). Prescription for Pharmacoeconomic Analysis: Methods for Cost-Utility Analysis. Auckland: PHARMAC.
35. Raftery, J. (2006). Review of NICE's rec- ommendations, 1999-2005. BMJ 332, 1266-1268.
36. Rawlins, M. D., and Culyer, A. J. (2004). National Institute for Clinical Excellence and its value judgments. BMJ 329, 224-227
37. Sendi, P., Gafni, A., and Birch, S. (2002). Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 11, 23-31.
38. Sermet, C., Andrieu, V., Godman, B., Van, G. E., Haycox, A., and Reynier, J. P. (2010). Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24.
39. Simoens, S., and De Coster, S. (2006). Potential savings from increased substitution of generic for originator medicines in Europe. J. Generic Med. 4, 43-45.
40. Stinnett, A. A., and Mullahy, J. (1998). Net health benefits: a new framework for the analysis of uncertainty in cost- effectiveness analysis. Med. Decis. Making 18, S68-S80.
41. Tilson, L., and Barry, M. (2010). Recent developments in pharmacoeconomic evaluation in Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 10, 221-224.
42. Timoney, A., Walker, A., Paterson, K., Bennie, M., McIver, L., and Webb, D. (2006). The Scottish Medicine Consortium - Are Oncology Medicines Different? Adelaide: Third Health Technology Assessment International Conference.
43. Van Wilder, P., and Dupont, A. (2008). Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 11, 784-787.
44. Webb, D. (2009). Early Assessment of Cost- Effectiveness, 14-7-2009. Edinburgh: Congress of the European Association for Clinical Pharmacology and Therapeutics.
45. Weinstein, M. C. (1988). A QALY is a QALY - or is it? J. Health Econ. 7, 289-290.
46. Weinstein, M. C., and Zeckhauser, R. (1973). Critical ratios and effi- cient allocation. J. Public Econ. 2, 147-157.
47. Wettermark, B., Godman, B., Andersson, K., Gustafsson, L. L., Haycox, A., and Bertele, V. (2008). Recent national and regional drug reforms in Sweden: implications for pharmaceutical com- panies in Europe. Pharmacoeconomics 26, 537-550.
48. WHO Commission on Macroeconomics and Health. (2001). Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organisation.
49. Williams, A. (2004). What Could be Nicer than NICE? London: Office of Health Economics.